Back to Journals » OncoTargets and Therapy » Volume 7

More than 9 years of continuous trastuzumab treatment in metastatic breast cancer without cardiac toxicity: a case report and literature review

Authors Badulescu F, Badulescu A, Paul D, Popescu CF, Florescu C

Received 13 June 2014

Accepted for publication 12 August 2014

Published 17 October 2014 Volume 2014:7 Pages 1911—1917

DOI https://doi.org/10.2147/OTT.S69343

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Faris Farassati


Florin Badulescu,1 Adriana Badulescu,2 Doru Paul,3 Carmen Florina Popescu,4 Cristina Florescu5

1Department of Oncology, Universitatea de Medicina si Farmacie, Craiova, Romania; 2Department of Surgery, Universitatea Titu Maiorescu, Bucuresti, Romania; 3Monter Cancer Center, North Shore LIJ Cancer Institute, Lake Success, NY, USA; 4Department of Pathology, Spitalul Universitar Clinic de Urgenta, Craiova, Romania; 5Department of Cardiology, Universitatea de Medicina si Farmacie, Craiova, Romania

Abstract: The main concern of long-term use of trastuzumab remains its association with potential cardiac side effects. Although these side effects are real, they are probably overemphasized. We report the case of a woman with metastatic breast cancer, who is currently in complete remission, and who received trastuzumab continuously for more than 9 years, without any significant cardiac toxicity.

Keywords: metastatic breast cancer, long survival, trastuzumab

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]